JPJoel S. Pachter

Joel S. Pachter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joel S. Pachter has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polarized release of brain microvascular endothelial cell-derived extracellular vesicles supports leukocyte transendothelial migration in vitro

    by Dylan Krajewski, Shujun Ge, Evan R. Jellison, Yi Wu, Kalpani N. Udeni Galpayage Dona, Allison M. Andrews, Servio H. Ramirez, James L. McGrath, Samuel J. W. Chan, Ji-Yu Zhu, et al.

  • Open Access

    Polarized release of brain microvascular endothelial cell- derived extracellular vesicles is functionally coupled to leukocyte transendothelial migration

    by Dylan Krajewski, Shujun Ge, Evan R. Jellison, Yi Wu, Kalpani N. Udeni Galpayage Dona, Allison M. Andrews, Servio H. Ramirez, James L. McGrath, Samuel J.W. Chan, Ji-Yu Zhu, et al.

    Background Abundant evidence indicates extracellular vesicles (EVs) (exosomes and microvesicles) are mediators of intercellular communication. Previous reports from this group further showed that EVs from brain microvascular endothelial cells (BMEC) transferred the tight junction protein (TJ) claudin-5 (CLN-5) to leukocytes in vitro and during experimental autoimmune encephalomyelitis, leading us to hypothesize that such interaction might facilitate transendothelial migration (TEM) by a “zipper mechanism” whereby CLN-5 molecules on leukocyte-bound EVs temporarily replace those at interendothelial junctions. Such a mechanism is likely to be under strict spatiotemporal control. A corollary to this is that EVs are released from BMEC in a polar manner, such that only those released from the apical surface interact with leukocytes, while those from the basolateral surface bind adventitial targets. Methods To assess polar EV release from BMEC and subsequent BMEC EV:leukocyte interactions during TEM using transwell assays, flow cytometry, nanoparticle tracking, super-resolution and live-time imaging were used. Results It was shown that EV release was highly polarized, as EVs accumulated predominantly in the chamber facing their membrane of origin. Supportive of polarized exosome release, apical and basolateral membrane material appeared segregated into discrete multivesicular body populations. Consistent with a role in TEM, apical-derived BMEC EVs preferentially bound leukocytes in a manner dependent on leukocyte adhesion, with TEM suppressed when EV release was inhibited. Polarized EV release was maintained under physiological flow, wherein CLN-5 + EVs exhibited near exclusive release at the apical surface, possibly reflecting their predisposition toward interacting with circulating immune cells. Conclusion BMEC EVs are released in a polarized manner and those derived from the apical surface focally interact with adherent leukocytes. That inhibition of EV release further suppressed TEM suggests that BMEC EV:leukocyte binding is functionally coupled to the TEM process.

  • Open Access

    Proteomic interrogation of the meninges reveals the molecular identities of structural components and regional distinctions along the CNS axis

    by Elise Santorella, Jeremy L. Balsbaugh, Shujun Ge, Parisa Saboori, David Baker, Joel S. Pachter

    The meninges surround the brain and spinal cord, affording physical protection while also serving as a niche of neuroimmune activity. Though possessing stromal qualities, its complex cellular and extracellular makeup has yet to be elaborated, and it remains unclear whether the meninges vary along the neuroaxis. Hence, studies were carried-out to elucidate the protein composition and structural organization of brain and spinal cord meninges in normal, adult Biozzi ABH mice. First, shotgun, bottom-up proteomics was carried-out. Prominent proteins at both brain and spinal levels included Type II collagen and Type II keratins, representing extracellular matrix (ECM) and cytoskeletal categories, respectively. While the vast majority of total proteins detected was shared between both meningeal locales, more were uniquely detected in brain than in spine. This pattern was also seen when total proteins were subdivided by cellular compartment, except in the case of the ECM category where brain and spinal meninges each had near equal number of unique proteins, and Type V and type III collagen registered exclusively in the spine. Quantitative analysis revealed differential expression of several collagens and cytoskeletal proteins between brain and spinal meninges. High-resolution immunofluorescence and immunogold-scanning electronmicroscopy on sections from whole brain and spinal cord – still encased within bone –identified major proteins detected by proteomics, and highlighted their association with cellular and extracellular elements of variously shaped arachnoid trabeculae. Western blotting aligned with the proteomic and immunohistological analyses, reinforcing differential appearance of proteins in brain vs spinal meninges. Results could reflect regional distinctions in meninges that govern protective and/or neuroimmune functions.


  • Open Access

    Proteomic interrogation of the meninges reveals the molecular identities of structural components and regional distinctions along the CNS axis

    by Elise Santorella, Jeremy L. Balsbaugh, Shujun Ge, Parisa Saboori, David Baker, Joel S. Pachter

    The meninges surround the brain and spinal cord, affording physical protection while also serving as a niche of neuroimmune activity. Though possessing stromal qualities, its complex cellular and extracellular makeup has yet to be elaborated, and it remains unclear whether the meninges vary along the neuroaxis. Hence, studies were carried-out to elucidate the protein composition and structural organization of brain and spinal cord meninges in normal, adult Biozzi ABH mice. First, shotgun, bottom-up proteomics was carried-out. Prominent proteins at both brain and spinal levels included Type II collagen and Type II keratins, representing extracellular matrix (ECM) and cytoskeletal categories, respectively. While the vast majority of total proteins detected was shared between both meningeal locales, more were uniquely detected in brain than in spine. This pattern was also seen when total proteins were subdivided by cellular compartment, except in the case of the ECM category where brain and spinal meninges each had near equal number of unique proteins, and Type V and type III collagen registered exclusively in the spine. Quantitative analysis revealed differential expression of several collagens and cytoskeletal proteins between brain and spinal meninges. High-resolution immunofluorescence and immunogold-scanning electronmicroscopy on sections from whole brain and spinal cord – still encased within bone –identified major proteins detected by proteomics, and highlighted their association with cellular and extracellular elements of variously shaped arachnoid trabeculae. Western blotting aligned with the proteomic and immunohistological analyses, reinforcing differential appearance of proteins in brain vs spinal meninges. Results could reflect regional distinctions in meninges that govern protective and/or neuroimmune functions.

  • Open Access

    Appearance of claudin-5+ leukocyte subtypes in the blood and CNS during progression of EAE

    by Dylan Krajewski, Debayon Paul, Shujun Ge, Evan Jellison, Joel S. Pachter

    Background: Tight junctions (TJs) are membrane specializations characteristic of barrier-forming membranes, which function to seal the aqueous pathway between endothelial cells or epithelial cells and, thereby, obstruct intercellular solute and cellular movement. However, previous work from our laboratory found that claudin-5 (CLN-5), a TJ protein prominent at the blood–brain barrier (BBB), was also detected, ectopically, on leukocytes (CLN-5+) in the blood and central nervous system (CNS) of mice with experimental autoimmune encephalomyelitis (EAE), a neuroinflammatory, demyelinating disease that is a model for multiple sclerosis. CLN-5 was further shown to be transferred from endothelial cells to circulating leukocytes during disease, prompting consideration this action is coupled to leukocyte transendothelial migration (TEM) into the CNS by fostering transient interactions between corresponding leukocyte and endothelial junctional proteins at the BBB.Methods: To begin clarifying the significance of CLN-5+leukocytes, flow cytometry was used to determine their appearance in the blood and CNS during EAE.Results: Flow cytometric analysis revealed CLN-5+populations among CD4 and CD8 T cells, B cells, monocytes and neutrophils, and these appeared with varying kinetics and to different extents in both blood and CNS. CLN-5 levels on circulating T cells further correlated highly with activation state. And, the percentage of CLN-5+cells among each of the subtypes analyzed was considerably higher in CNS tissue than in blood, consistent with the interpretation that CLN-5+leukocytes gain preferred access to the CNS.Conclusion: Several leukocyte subtypes variably acquire CLN-5 in blood before they enter the CNS, an event that may represent a novel mechanism to guide leukocytes to sites for paracellular diapedesis across the BBB.


  • Open Access

    Appearance of Claudin-5+ Leukocyte Subtypes in the Blood and CNS During Progression of EAE

    by Dylan Krajewski, Debayon Paul, Shujun Ge, Evan Jellison, Joel S. Pachter

    Background: Tight junctions (TJs) are membrane specializations characteristic of barrier-forming membranes, which function to seal the aqueous pathway between endothelial cells or epithelial cells and, thereby, obstruct intercellular solute and cellular movement. However, previous work from our laboratory found that claudin-5 (CLN-5), a TJ protein prominent at the blood-brain barrier (BBB), is also detected, ectopically, on leukocytes (CLN-5+) in the blood and central nervous system (CNS) of mice with experimental autoimmune encephalomyelitis (EAE), a neuroinflammatory, demyelinating disease that is a model for multiple sclerosis. CLN-5 was further shown to be transferred from endothelial cells to circulating leukocytes during disease, prompting consideration this action is coupled to leukocyte transendothelial migration (TEM) into the CNS by fostering transient interactions between corresponding leukocyte and endothelial junctional proteins at the BBB. Methods: To begin clarifying the significance of CLN-5+ leukocytes, flow cytometry was used to determine their appearance in the blood and CNS during EAE. Results: Flow cytometric analysis revealed CLN-5+ populations among CD4 and CD8 T cells, B cells, monocytes and neutrophils, and these appeared with varying kinetics and to different extents in both blood and CNS. CLN-5 levels on circulating T cells further correlated highly with activation state. And, percentage of CLN-5+ cells among each of the subtypes analyzed was considerably higher in CNS tissue than in blood, consistent with the interpretation that CLN-5+ leukocytes gain preferred access to the CNS. Conclusion: Several leukocyte subtypes variably acquire CLN-5 in blood before they enter the CNS, an event that may represent a novel mechanism to guide leukocytes to sites for paracellular diapedesis across the BBB.

  • Open Access

    Systemic TLR2 tolerance enhances central nervous system remyelination

    by Nicholas J. Wasko, Meghan Horne Kulak, Debayon Paul, Alexandra M. Nicaise, Stephen T. Yeung, Frank C. Nichols, Kamal M. Khanna, Stephen Crocker, Joel S. Pachter, Robert B. Clark

    Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by both inflammatory demyelination and impaired remyelination. Studies indicate that Toll-like receptor 2 (TLR2) signaling contributes to both the inflammatory component and the defective remyelination in MS. While most MS therapeutics target adaptive immunity, we recently reported that reducing TLR2 signaling in innate immune cells by inducing TLR2 tolerance attenuates adoptively transferred experimental autoimmune encephalomyelitis. Given that previous reports suggest TLR2 signaling also inhibits myelin repair, the objective of this study was to assess how reducing TLR2 signaling through TLR2 tolerance induction affects CNS myelin repair. Chow containing 0.2% cuprizone was fed to male and female wild-type (WT) C57BL/6 mice or TLR2-deficient (TLR2−/−) mice for 5 weeks to induce demyelination. During a 2-week remyelination period following discontinuation of cuprizone, WT mice received either low dose TLR2 ligands to induce systemic TLR2 tolerance or vehicle control (VC). Remyelination was evaluated via electron microscopy and immunohistochemical analysis of microglia and oligodendrocytes in the corpus callosum. Statistical tests included 2-way ANOVA and Mann-Whitney U analyses. Inducing TLR2 tolerance in WT mice during remyelination significantly enhanced myelin recovery, restoring unmyelinated axon frequency and myelin thickness to baseline levels compared to VC-treated mice. Mechanistically, enhanced remyelination in TLR2 tolerized mice was associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS+ phenotype to a non-inflammatory/pro-repair Arg1+ phenotype. This result was confirmed in vitro by inducing TLR2 tolerance in WT microglia cultures. TLR2−/− mice, without TLR2 tolerance induction, also significantly enhanced myelin recovery compared to WT mice, adding confirmation that reduced TLR2 signaling is associated with enhanced remyelination. Our results suggest that reducing TLR2 signaling in vivo by inducing TLR2 tolerance significantly enhances myelin repair. Furthermore, the enhanced remyelination resulting from TLR2 tolerance induction is associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS+ phenotype to a non-inflammatory/pro-repair Arg1+ phenotype. While deletion of TLR2 would be an impractical approach in vivo, reducing innate immune signaling through TLR2 tolerance induction may represent a novel, two-pronged approach for treating both inflammatory and myelin repair components of MS.


  • Open Access

    Human ES-derived MSCs correct TNF-α-mediated alterations in a blood–brain barrier model

    by Shujun Ge, Xi Jiang, Debayon Paul, Li Song, Xiaofang Wang, Joel S. Pachter

    Immune cell trafficking into the CNS is considered to contribute to pathogenesis in MS and its animal model, EAE. Disruption of the blood–brain barrier (BBB) is a hallmark of these pathologies and a potential target of therapeutics. Human embryonic stem cell-derived mesenchymal stem/stromal cells (hES-MSCs) have shown superior therapeutic efficacy, compared to bone marrow-derived MSCs, in reducing clinical symptoms and neuropathology of EAE. However, it has not yet been reported whether hES-MSCs inhibit and/or repair the BBB damage associated with neuroinflammation that accompanies EAE. BMECs were cultured on Transwell inserts as a BBB model for all the experiments. Disruption of BBB models was induced by TNF-α, a pro-inflammatory cytokine that is a hallmark of acute and chronic neuroinflammation. Results indicated that hES-MSCs reversed the TNF-α-induced changes in tight junction proteins, permeability, transendothelial electrical resistance, and expression of adhesion molecules, especially when these cells were placed in direct contact with BMEC. hES-MSCs and/or products derived from them could potentially serve as novel therapeutics to repair BBB disturbances in MS.


  • Open Access

    Extracellular vesicles: mediators and biomarkers of pathology along CNS barriers

    by Servio H. Ramirez, Allison M. Andrews, Debayon Paul, Joel S. Pachter

    Extracellular vesicles (EVs) are heterogeneous, nano-sized vesicles that are shed into the blood and other body fluids, which disperse a variety of bioactive molecules (e.g., protein, mRNA, miRNA, DNA and lipids) to cellular targets over long and short distances. EVs are thought to be produced by nearly every cell type, however this review will focus specifically on EVs that originate from cells at the interface of CNS barriers. Highlighted topics include, EV biogenesis, the production of EVs in response to neuroinflammation, role in intercellular communication and their utility as a therapeutic platform. In this review, novel concepts regarding the use of EVs as biomarkers for BBB status and as facilitators for immune neuroinvasion are also discussed. Future directions and prospective are covered along with important unanswered questions in the field of CNS endothelial EV biology.